电子鼻呼气分析:间质性肺疾病的新型诊断工具
该横断面研究纳入322例间质性肺疾病(ILD)患者和48例健康对照,采用电子鼻(SpiroNose)分析呼气,评估其区分ILD与健康对照及鉴别ILD亚组的准确性。结果显示电子鼻可完全区分ILD与健康对照(训练集和验证集AUC均为1.00),鉴别IPF与其他ILD的验证集AUC为0.87(95%CI 0.77-0.96),区分各亚组的AUC为0.85-0.99。
要点
- 电子鼻呼气分析可完全区分ILD患者与健康对照,训练集和验证集AUC均为1.00。
- 鉴别IPF与其他ILD的验证集AUC为0.87(95%CI 0.77-0.96)。
- 电子鼻可可靠区分不同ILD亚组,AUC范围为0.85-0.99。
核心结论
- 电子鼻技术可完全区分ILD患者与健康对照,并能准确鉴别不同ILD亚组。
- 呼气分析 using eNose technology 可能成为ILD的新型生物标志物,有助于未来实现及时诊断。
研究设计与样本
- 横断面研究,连续纳入ILD患者和健康对照,使用电子鼻(SpiroNose)分析呼气。
- 统计分析采用偏最小二乘判别分析和受试者工作特征分析,较大亚组使用独立训练集和验证集(2:1)。
- 共纳入322例ILD患者和48例健康对照;ILD包括结节病(n=141)、IPF(n=85)、结缔组织病相关ILD(n=33)、慢性过敏性肺炎(n=25)、特发性非特异性间质性肺炎(n=10)、具有自身免疫特征的间质性肺炎(n=11)和其他ILD(n=17)。
主要发现
- 电子鼻传感器区分ILD与健康对照,训练集和验证集AUC均为1.00。
- 比较IPF与其他ILD患者,训练集AUC为0.91(95%CI 0.85-0.96),验证集AUC为0.87(95%CI 0.77-0.96)。
- 电子鼻可靠区分各别疾病,AUC值范围为0.85至0.99。
临床怎么用
- 电子鼻呼气分析可作为ILD无创诊断的潜在工具,辅助区分ILD与健康对照及鉴别亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Early and accurate diagnosis of interstitial lung diseases (ILDs) remains a major challenge. Better noninvasive diagnostic tools are much needed. We aimed to assess the accuracy of exhaled breath analysis using eNose technology to discriminate between ILD patients and healthy controls, and to distinguish ILD subgroups. METHODS: In this cross-sectional study, exhaled breath of consecutive ILD patients and healthy controls was analysed using eNose technology (SpiroNose). Statistical analyses were done using partial least square discriminant analysis and receiver operating characteristic analysis. Independent training and validation sets (2:1) were used in larger subgroups. RESULTS: A total of 322 ILD patients and 48 healthy controls were included: sarcoidosis (n=141), idiopathic pulmonary fibrosis (IPF) (n=85), connective tissue disease-associated ILD (n=33), chronic hypersensitivity pneumonitis (n=25), idiopathic nonspecific interstitial pneumonia (n=10), interstitial pneumonia with autoimmune features (n=11) and other ILDs (n=17). eNose sensors discriminated between ILD and healthy controls, with an area under the curve (AUC) of 1.00 in the training and validation sets. Comparison of patients with IPF and patients with other ILDs yielded an AUC of 0.91 (95% CI 0.85-0.96) in the training set and an AUC of 0.87 (95% CI 0.77-0.96) in the validation set. The eNose reliably distinguished between individual diseases, with AUC values ranging from 0.85 to 0.99. CONCLUSIONS: eNose technology can completely distinguish ILD patients from healthy controls and can accurately discriminate between different ILD subgroups. Hence, exhaled breath analysis using eNose technology could be a novel biomarker in ILD, enabling timely diagnosis in the future.
引用
- Moor CC, Oppenheimer JC, Nakshbandi G, et al. Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. Eur Respir J. 2021. PMID: 32732331. doi:10.1183/13993003.02042-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。